research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication used to treat skin diseases like harlequin-type ichthyosis, lamellar ichthyosis, and severe cystic acne or moderate acne that is unresponsive to antibiotics. Isotretinoin is used off-label to treat basal cell carcinoma and squamous cell carcinoma, although clinical evidence suggests it is not effective in this setting. It is a retinoid, meaning it is related to vitamin A, and is found in small quantities naturally in the body. Its isomer, tretinoin, is also an acne drug. In its pure form, isotretinoin is an orange powder. The most common adverse effects are dry lips (cheilitis), dry and fragile skin (xeroderma), dry eyes and an increased susceptibility to sunburn. Uncommon and rare side effects include muscle aches and pains (myalgias), headaches, and depression in some users. Some of those side effects can persist long after the discontinuation of the use of the drug. Isotretinoin may cause liver failure, therefore the patient's blood levels should be regularly tested. It is known to cause birth defects due to in-utero exposure because of the molecule's close resemblance to retinoic acid, a natural vitamin A derivative that controls normal embryonic development. It is associated with psychiatric side effects, most commonly depression, and more rarely, psychosis and unusual behaviors. Other rare side effects include hyperostosis and premature epiphyseal closure, which have been reported to be persistent.
== Concerns == Although green nanotechnology poses many advantages over traditional methods, there is still much debate about the concerns brought about by nanotechnology. For example, since the nanoparticles are small enough to be absorbed into skin and/or inhaled, countries are mandating that additional research revolving around the impact of nanotechnology on organisms be heavily studied. In fact, the field of eco-nanotoxicology was founded solely to study the effect of nanotechnology on earth and all of its organisms. At the moment, scientists are unsure of what will happen when nanoparticles seep into soil and water, but organizations, such as NanoImpactNet, have set out to study these effects.
First Minister of Wales Eluned Morgan offers Plaid Cymru an open invitation to support the Welsh Government's budget, scheduled to be delivered by Finance Secretary Mark Drakeford on 10 December. Wales's health secretary, Jeremy Miles announces that private healthcare will be used to help reduce the patient backlog in the NHS, with £50m allocated for health to be given to Wales's health boards to provide more appointments, tests and treatments. 20 November – Peter Kyle, the Secretary of State for Science, Innovation and Technology, tells the BBC that a ban on social media for under-16s in the UK is "on the cards". 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. 22 November – Downing Street indicates that Israeli prime minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. Former prime minister Gordon Brown publicly declares his opposition to a new law on assisted dying. 23 November – The UK government advertises for a new negotiator which it hopes will deliver a "reset" of the UK's relationship with the European Union. Secretary of State for Justice Shabana Mahmood writes to her constituents saying she is "profoundly concerned" about the Terminally Ill Adults (End of Life) Bill, not only for religious reasons but because of what it would mean for the state if one of its roles became helping people to die.
Sources: en.wikipedia.org
=== Litra symbol === The Roman libra and Byzantine lítra (λίτρα), which served as both the pound mass unit and liter volume unit, were abbreviated in Greek using lambda with modified forms of the iota subscript ⟨λͅ⟩. These are variously encoded in Unicode. The Ancient Greek Numbers Unicode block includes 10183 greek litra sign (𐆃) as well as 𐅢, which is described as 10162 greek acrophonic hermionian ten but was much more common as a form of the litra sign. A variant of the sign can be formed from 0338 combining long solidus overlay and either 039B greek capital letter lamda (Λ̸) or 03BB greek small letter lamda (λ̸).
The treaty stipulated that East Germany would unify its territory with Federal Republic of Germany via Article 23 of the Basic Law, meaning that East Germany and the Volkskammer would cease to exist. The chamber's last legislative period therefore only lasted four and a half months. The treaty took effect on 3 October 1990; on the same day, 144 of the 400 Volkskammer deputies became members of the Bundestag (63 from the CDU, 33 from the SPD, 24 from the PDS, 9 from the BFD, 8 from the DSU, and 7 from Alliance 90 and the Green Party). The 8 DSU members joined the CDU/CSU Bundestag Group, briefly renamed CDU/CSU/DSU. The distribution of seats between these parties was determined by recalculating the results of the 1990 elections on a per-state basis. Their tenure came to an end two months later with the first all-German federal election on 2 December 1990.
==== Sepsis ==== A variety of factors associated with sepsis may cause cholestasis. Typically, patients have conjugated hyperbilirubinemia and alkaline phosphatase (ALP) elevation but not to extreme levels. Sepsis-induced cholestasis may occur due to increased serum lipopolysaccharide levels. Lipopolysaccharides can inhibit and down-regulate bile salt transporters in hepatocytes, thereby leading to cholestasis. As such, in the case of sepsis, cholestasis occurs not as a result of impaired obstruction but rather the disruption of bile flow. Ischemic liver injury resulting from sepsis can also cause cholestasis. Importantly, jaundice is not indicative of cholestasis in all cases. Widespread hemolysis resulting from sepsis may release bilirubin, thereby overwhelming bilirubin reabsorption and excretion mechanism.
Sokolniki Park—in the 18th century, the home of the tsar's falconers well outside Moscow—became contiguous with the expanding city during the later 19th century and was developed into a municipal park in 1878. The suburban Savyolovsky Rail Terminal was built in 1902. In January 1905, the institution of the City Governor, or Mayor, was officially introduced; Alexander Adrianov became Moscow's first official mayor. When Catherine II assumed power in 1762, observers depicted the city's filth and the smell of sewage as symptoms of the disorderly lifestyles of lower-class Russians recently arrived from the farms. Elites called for improved sanitation, which became part of Catherine's plans for increased control over social life. National political and military successes from 1812 through 1855 calmed her critics and validated efforts to produce a more enlightened and stable society. The poor state of public health was discussed less often. However, in the wake of Russia's failures in the Crimean War in 1855–1856, confidence in the state's ability to maintain order in the slums eroded; therefore, demands for improved public health put this issue back on the public agenda. In 1903, the Moskvoretskaya water supply was completed.
Sources: en.wikipedia.org
TGFK-09SD, or TGFK09SD, is a serotonin 5-HT1A receptor agonist which is or was under development for the treatment of female sexual dysfunction but was never marketed. It is taken orally. The drug was developed by Fabre-Kramer Pharmaceuticals. As of January 2016, it is in phase 2 clinical trials. There have been no further updates on the development of the drug since then. The chemical structure of TGFK-09SD does not yet appear to have been disclosed.
Operation began with the Type T.3026 transmitter sending a pulse of radio energy into the transmission antennas from a hut beside the towers. Each station had two T.3026s, one active and one standby. The signal filled space in front of the antenna, flooding the entire area. Due to the transmission effects of the multiple stacked antennas, the signal was most strong directly along the line of shoot, and dwindled on either side. An area about 50 degrees to either side of the line was filled with enough energy to make detection practical. The Type T.3026 transmitter was provided by Metropolitan-Vickers, based on a design used for a BBC transmitter at Rugby. A unique feature of the design was the "demountable" valves, which could be opened for service, and had to be connected to an oil diffusion vacuum pump for continual evacuation while in use. The valves were able to operate at one of four selected frequencies between 20 and 55 MHz, and switched from one to another in 15 seconds. To produce the short pulses of signal, the transmitter consisted of Hartley oscillators feeding a pair of tetrode amplifier valves. The tetrodes were switched on and off by a pair of mercury vapour thyratrons connected to a timing circuit, the output of which biased the control and screen grids of the tetrode positively while a bias signal kept it normally turned off. Stations were arranged so their fan-shaped broadcast patterns slightly overlapped to cover gaps between the stations.
== Cultivation == The plants are propagated by cuttings about 40 to 50 cm (16 to 20 in) long, usually cultivars selected both for yield and quality of fruit. These are tied up to neighbouring trees or climbing frames at distances of about 2 m (6+1⁄2 ft) apart; trees with rough bark are favoured over those with smooth bark, as the pepper plants climb rough bark more readily. Competing plants are cleared away, leaving only sufficient trees to provide shade and permit free ventilation. The roots are covered in leaf mulch and manure, and the shoots are trimmed twice a year. On dry soils, the young plants require watering every other day during the dry season for the first three years. The plants bear fruit from the fourth or fifth year, and then typically for seven years. Harvesting begins as soon as one or two fruits at the base of the spikes begin to turn red, and before the fruit is fully mature, and still hard; if allowed to ripen completely, the fruits lose pungency, and ultimately fall off and are lost. The spikes are collected and spread out to dry in the sun, then the peppercorns are stripped off the spikes.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.